The growth of the plasma fractionation market can be attributed to the factors such as a rise in the use of prophylactic treatment for immune & bleeding diseases and increased diagnosis rate worldwide. Ongoing growth in geriatric population and increasing use of the alpha-1-antitrypsin and immunoglobulin for various chronic diseases is likely to contribute to the growth of the global plasma fractionation market. Additionally, the rising incidence of the immunological and neurological diseases worldwide along with the increasing use of intravenous immunoglobulin in various therapeutic areas are boosting the growth of the global plasma fractionation market.
According to the Value Market Research, the Global Plasma Fractionation Market is estimated to grow at CAGR 7% from USD 19,875.5 MN in 2017 and reach USD 31,710.5 MN by 2024.
IMMUNOGLOBINS TO GAIN THE MOMENTUM
Immunoglobins product segment is the leading segment in 2017 owing to the growing incidence of chronic inflammatory demyelinating polyneuropathy and hypogammaglobulinemia disease coupled with a rise in the use of immunoglobulins to treat Guillain-Barre syndrome, inflammatory myopathies, and specific antibody deficiency disorder. By end of 2024, Immunoglobins is expected to reach USD 14,130.7 MN. In addition, the geriatric population and the emergence of advanced technologies, and enhanced purification techniques are the other key factors that support the growth of the segment.
IMMUNOLOGY EMERGED AS HIGHLY PREFERRED APPLICATION AREA
Immunology is the dominating segment owing to the rising prevalence of immunodeficient disorder across the globe. Immunoglobulin is the most common protein used in blood fraction. Immunoglobulins, also known as antibodies, are glycoprotein molecules released by plasma cells (white blood cells). Basically, they act as a critical part of the immune response by specifically identifying and binding to specific antigens, such as bacteria or viruses, and supporting in their destruction. The high growth of this segment can be attributed to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders.
HOSPITAL & CLINICS TO LEAD THE SEGMENT
The hospitals & clinics end-user segment is dominating in 2017, owing to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders across hospital & clinics. Also, a growing number of the hospital along with an increase in healthcare expenditure is likely to push the growth of the segment uphill. Additionally, owing to the large patient pool treated in hospitals; expansion of hospitals & clinics across the globe along with the increasing number of collaborations between the manufacturers of plasma products and hospitals are again expected to propel the market of plasma fractionation.
NORTH AMERICA EMERGED AS THE LARGEST REGION IN THE GLOBAL MARKET FOR PLASMA FRACTIONATION
From the geographical perspective, in 2017, North America held the largest market share in the global plasma fractionation market due to increased use of immunoglobulin in the treatment of neurological diseases coupled with the use of the prophylaxis treatments to diagnosed patients. Moreover, increasing number of hemophilic patients in North America is also expected to boost the market growth in the region.
MAJOR COMPETITORS IN MARKET
Baxter International Inc., CSL Limited, Grifols, S.A., Octapharma AG, Bio Products Laboratory Ltd., Kedrion S.P.A., Shire Plc., Shanghai Raas, Hualan Biological Engineering Inc., Biotest AG, China Biologic Products Holdings, Inc., The LFB Group, Sanquin, Japan Blood Products Organization, and Green Cross Corp.
As per this study the global plasma fractionation market was valued at USD 25.58 MN (by revenue) in 2021 and is anticipated to reach USD 42.44 MN by 2028 with a CAGR of 7.5%.
Plasma fractionation is a process of extracting various components of blood-derived plasma. It acts as nature's raw material which is used in dozens of life-saving treatments and medications. The process of plasma fractionation is used to treat protein deficiency disorders in the healthcare sector. The major function of plasma fractionation is to remove or inactivate the virus and prions. Plasma contains various proteins including immunoglobulins, albumin, and clotting proteins such as fibrinogen. Among these albumin constitutes about 60% of the total protein in plasma and is present at concentrations between 35 and 55 mg/ml. It is the key factor responsible to the osmotic pressure of the blood and it functions as a carrier molecule for molecules with low water solubilities such as lipid-soluble hormones, pharmaceutical compounds, enzymes, metal ions, and fatty acids.
Market Dynamics
Ongoing growth in geriatric population and rising prevalence's of the immunological and neurological diseases coupled with increasing use of intravenous immunoglobulin in various therapeutic areas are likely to boost the market growth. In addition, increasing use of the alpha-1-antitrypsin and immunoglobulin for various chronic diseases is further adding impetus growth of the global plasma fractionation market. However, expensive treatment and strict governmental policy are likely to limit the market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of plasma fractionation.
Market Segmentation
The broad plasma fractionation market has been sub-grouped into product, application and end-user. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
By Product
- Albumin
- Immunoglobulins
- Coagulation Factor Concentrates
- Others
By Application
- Neurology
- Hematology
- Immunology
- Critical Care
- Others
By End-User
- Hospitals and Clinics
- Clinical Research Laboratories
- Academic Institutes
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for plasma fractionation in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Global Plasma Fractionation Market Share by Region (Representative Graph)
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the plasma fractionation market include Baxter International Inc., CSL Limited, Grifols, S.A., Octapharma AG, Bio Products Laboratory Ltd., Kedrion S.P.A., Shire Plc., Shanghai Raas, Hualan Biological Engineering Inc., Biotest AG, China Biologic Products Holdings, Inc., The LFB Group, Sanquin, Japan Blood Products Organization and Green Cross Corp. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.